Early Alzheimer'
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patient 1)First-time respondent to this study questionnaire 2)Diagnosed with early AD and initiated lecanemab treatment 3)At least 6 months have passed since lecanemab treatment initiation 4)Written informed consent obtained based on the patient's free will 5)Age 18 years or older Family care partner 1)First-time respondent to this study questionnaire 2)Provides daily support or caregiving to an eligible patient 3)Written informed consent obtained 4)Age 18 years or older
Exclusion criteria
Exclusion criteria: Patient Unable to complete the questionnaire by themselves or via designated family assistance Family care partner Unable to complete the questionnaire
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment satisfaction among patients and their family care partners | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment understanding, treatment engagement, perceived treatment effects, other concerns (including aspects of the patient's daily functioning), and qualitative responses (free-text) among family care partners. | — |
Countries
Japan
Contacts
Eisai Co., Ltd Medical Headquarters, Neurology Department